Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
35.34
-1.16 (-3.18%)
At close: Oct 23, 2026, 4:00 PM EDT
35.35
+0.01 (0.03%)
After-hours: Oct 23, 2026, 7:47 PM EDT
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 19 analysts polled by S&P Global, Xenon Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $71.94. The average 1-year stock price forecast is 103.57% higher than the current stock price, while the lowest is $46 (+30.16%) and the highest is $90 (+154.67%).
Price Target: $71.94 (+103.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 15 | 15 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 20 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $64 | Buy | Maintains | $64 | +81.10% | Oct 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $77 | Buy | Maintains | $77 | +117.88% | Oct 12, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $73 | Buy | Initiates | $73 | +106.56% | Oct 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $70 | Buy | Maintains | $70 | +98.08% | Oct 1, 2026 |
| Bloom Burton | Bloom Burton | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +100.91% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
1.26M
from 7.50M
Decreased by -83.24%
Revenue Next Year
26.97M
from 1.26M
Increased by 2,045.70%
EPS This Year
-4.63
from -4.36
EPS Next Year
-4.72
from -4.63
EPS and Forward PE are based on non-GAAP adjusted numbers.